Trustees of Columbia University in the City of New York Makes New $328,000 Investment in Vigil Neuroscience, Inc. (NASDAQ:VIGL)

Trustees of Columbia University in the City of New York bought a new stake in Vigil Neuroscience, Inc. (NASDAQ:VIGL) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 192,973 shares of the company’s stock, valued at approximately $328,000. Vigil Neuroscience makes up approximately 0.1% of Trustees of Columbia University in the City of New York’s holdings, making the stock its 7th biggest holding.

A number of other hedge funds and other institutional investors also recently made changes to their positions in VIGL. Blair William & Co. IL bought a new position in Vigil Neuroscience in the fourth quarter valued at about $551,000. Renaissance Technologies LLC lifted its holdings in shares of Vigil Neuroscience by 698.5% during the 4th quarter. Renaissance Technologies LLC now owns 367,300 shares of the company’s stock valued at $624,000 after purchasing an additional 321,300 shares in the last quarter. abrdn plc lifted its stake in Vigil Neuroscience by 124.9% in the 4th quarter. abrdn plc now owns 528,472 shares of the company’s stock valued at $898,000 after acquiring an additional 293,461 shares in the last quarter. 683 Capital Management LLC lifted its stake in Vigil Neuroscience by 14.8% in the 4th quarter. 683 Capital Management LLC now owns 1,400,000 shares of the company’s stock valued at $2,380,000 after acquiring an additional 180,420 shares in the last quarter. Finally, Boothbay Fund Management LLC bought a new stake in Vigil Neuroscience in the 4th quarter valued at approximately $249,000. 83.64% of the stock is currently owned by institutional investors and hedge funds.

Vigil Neuroscience Stock Up 7.3%

Shares of VIGL stock opened at $2.49 on Friday. Vigil Neuroscience, Inc. has a twelve month low of $1.31 and a twelve month high of $6.06. The company has a market cap of $116.21 million, a P/E ratio of -1.21 and a beta of 1.90. The business has a fifty day simple moving average of $1.94 and a 200 day simple moving average of $2.26.

Vigil Neuroscience (NASDAQ:VIGL) last announced its quarterly earnings data on Wednesday, May 7th. The company reported ($0.49) earnings per share for the quarter, topping the consensus estimate of ($0.53) by $0.04. As a group, equities research analysts anticipate that Vigil Neuroscience, Inc. will post -2.07 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

VIGL has been the topic of several recent analyst reports. Guggenheim reaffirmed a “buy” rating on shares of Vigil Neuroscience in a research report on Friday, January 24th. William Blair raised Vigil Neuroscience to a “strong-buy” rating in a report on Thursday, April 24th. Wedbush reaffirmed an “outperform” rating and issued a $13.00 price objective on shares of Vigil Neuroscience in a report on Monday, May 5th. Finally, HC Wainwright cut their target price on Vigil Neuroscience from $17.00 to $14.00 and set a “buy” rating for the company in a research report on Friday, March 14th. Four analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, Vigil Neuroscience currently has an average rating of “Buy” and a consensus price target of $16.25.

Vigil Neuroscience Company Profile

Vigil Neuroscience, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.